Extracellular vesicles-based biomarkers represent a promising liquid biopsy in endometrial cancer
EntityUAM. Departamento de Bioquímica
PublisherMDPI, Basel, Switzerland
10.3390/cancers11122000Cancers 11.12 (2019): 1-14
Funded byThis research was funded by Instituto de Salud Carlos III, grant PI17/01919, co-financed by the European Regional Development Fund (FEDER), and by Fundación Científica de la Asociación Española Contra el Cáncer (AECC), Grupos Clínicos Coordinados 2018. Carolina Herrero is supported by a predoctoral i-PFIS fellowship from Instituto de Salud Carlos III (IFI17/00047); Laura Muinelo is supported by Asociación Española Contra el Cáncer (AECC).
ProjectGobierno de España. PI17/01919,
SubjectsEVs; ExoGAG; Endometrial cancer; ANXA2; Medicina
Rights© 2019 by the authors. Licensee MDPI, Basel, Switzerland
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Tumor-derived extracellular vesicles (EVs) are secreted in large amounts into biological fluids of cancer patients. The analysis of EVs cargoes has been associated with patient´s outcome and response to therapy. However, current technologies for EVs isolation are tedious and low cost-e cient for routine clinical implementation. To explore the clinical value of circulating EVs analysis we attempted a proof-of-concept in endometrial cancer (EC) with ExoGAG, an easy to use and highly e cient new technology to enrich EVs. Technical performance was first evaluated using EVs secreted by Hec1A cells. Then, the clinical value of this strategy was questioned by analyzing the levels of two well-known tissue biomarkers in EC, L1 cell adhesion molecule (L1CAM) and Annexin A2 (ANXA2), in EVs purified from plasma in a cohort of 41 EC patients and 20 healthy controls. The results demonstrated the specific content of ANXA2 in the purified EVs fraction, with an accurate sensitivity and specificity for EC diagnosis. Importantly, high ANXA2 levels in circulating EVs were associated with high risk of recurrence and non-endometrioid histology suggesting a potential value as a prognostic biomarker in EC. These results also confirmed ExoGAG technology as a robust technique for the clinical implementation of circulating EVs analyses
Google Scholar:Herrero, Carolina - Fuente, Alexandre de la - Casas-Arozamena, Carlos - Sebastian, Víctor - Prieto, Martín - Arruebo, Manuel - Abalo, Alicia - Colás, Eva - Moreno Bueno, Gema - Gil-Moreno, Antonio - Vilar, Ana - Cueva, Juan - Abal, Miguel - Muinelo-Romay, Laura
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Genomic profiling of uterine aspirates and cfDNA as an integrative liquid biopsy strategy in endometrial cancer Casas-Arozamena, Carlos; Díaz, Eva; Moiola, Cristian Pablo; Alonso-Alconada, Lorena; Ferreiros, Alba; Abalo, Alicia; López Gil, Carlos; Oltra, Sara S.; Santiago, Javier de; Cabrera, Silvia; Sampayo, Victoria; Bouso, Marta; Arias, Efigenia; Cueva, Juan; Colas, Eva; Vilar, Ana; Gil-Moreno, Antonio; Abal, Miguel; Moreno Bueno, Gema; Muinelo-Romay, Laura